T4P 1001

Drug Profile

T4P 1001

Alternative Names: T4P1001

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Tools4Patient
  • Class Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuropathic pain; Pain

Most Recent Events

  • 08 Dec 2016 Tools4Patients plans a clinical trial for Pain, including Neuropathic pain and Osteoarthritic pain, in France and Belgium (PO) (NCT02989792)
  • 01 Oct 2016 Tools4Patient completes a phase II trial in Neuropathic pain and osteoarthritic Pain in Belgium and France (NCT02459197)
  • 01 Jul 2015 Phase-II clinical trials in Neuropathic pain in France (PO) (NCT02459197)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top